3SBio Inc Shs Unitary 144A/Reg S 01530
Trading Information
- Previous Close Price
- HKD 6.20
- Day Range
- HKD 6.17–6.37
- 52-Week Range
- HKD 4.91–8.10
- Bid/Ask
- HKD 6.31 / HKD 6.32
- Market Cap
- HKD 15.39 Bil
- Volume/Avg
- 4.5 Mil / 18.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 6.87
- Price/Sales
- 1.75
- Dividend Yield (Trailing)
- 1.61%
- Dividend Yield (Forward)
- 4.03%
- Total Yield
- 1.61%
Company Profile
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 5,411
- Website
- https://www.3sbio.com
Comparables
Valuation
|
Metric
|
01530
|
01167
|
02616
|
|---|---|---|---|
Price/Earnings (Normalized) | 6.87 | — | — |
Price/Book Value | 0.98 | 1.35 | — |
Price/Sales | 1.75 | 19.02 | 2.24 |
Price/Cash Flow | 6.04 | — | — |
Price/Earnings
01530
01167
02616
Financial Strength
|
Metric
|
01530
|
01167
|
02616
|
|---|---|---|---|
Quick Ratio | 2.62 | 5.67 | 1.42 |
Current Ratio | 2.88 | 5.70 | 1.56 |
Interest Coverage | 14.79 | −47.87 | −32.18 |
Quick Ratio
01530
01167
02616
Profitability
|
Metric
|
01530
|
01167
|
02616
|
|---|---|---|---|
Return on Assets (Normalized) | 9.33% | −22.98% | −38.51% |
Return on Equity (Normalized) | 15.92% | −33.40% | −157.15% |
Return on Invested Capital (Normalized) | 10.03% | −28.24% | −69.17% |
Return on Assets
01530
01167
02616
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lyfrgsmszw | Nmby | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fzwkvrjq | Knjyrq | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Svbmqdbmj | Dpqmvh | $97.3 Bil | |
MRNA
| Moderna Inc | Xswfmjzw | Ggvn | $42.7 Bil | |
ARGX
| argenx SE ADR | Ffvtdqxdp | Hkxg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ftxchsfj | Fgp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qftjpwwrn | Lnlfftt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wdhhqhbm | Yhtmj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dkvnbchr | Mtqfqqj | $12.6 Bil | |
INCY
| Incyte Corp | Yxqfqqhn | Nxkqmg | $11.8 Bil |